A 29-year-old female, who had undergone lobectomy plus therapeutic lymph node dissection for a 1.2-cm papillary thyroid cancer nodule with multiple nodal metastases, was referred to our institution for RRA, when she orally took L-thyroxine at a dose of 62.5 milligram (mg) per day, with a body weight of 55 kilogram (kg). After four weeks of L-thyroxine withdrawal before RRA, plain computed tomography scan showed no abnormal findings in the chest (no evidence of pleural disease), and the remaining left thyroid lobe (Figure 1A) measured 13 millimeter (mm) × 12 mm × 41 mm with normal blood flow by ultrasonography. All laboratory workup showed normal blood cell count, hepatic function, and thyroid function, with a thyroid-stimulating hormone (TSH) level of 2.86 mIU/L, a free triiodothyronine (FT3) level of 3.92 pmol/L, and a free thyroxine (FT4) level of 15.70 pmol/L (Figure 2).